Denali Therapeutics Secures Fast Track for Hunter Syndrome Drug with PDUFA April 2026
Denali Therapeutics’ tividenofusp alfa for Hunter syndrome holds Fast Track, Breakthrough Therapy and Priority Medicines designations with an FDA PDUFA target date of April 2026. The therapy requires precise protein engineering and scaled biomanufacturing to cross the blood-brain barrier for consistent, large-scale production.
1. Tividenofusp Alfa for Hunter Syndrome
Denali’s tividenofusp alfa is an investigational fusion protein therapy targeting Hunter syndrome, a rare lysosomal storage disorder. It is engineered to cross the blood-brain barrier and address central nervous system manifestations of the disease.
2. Regulatory Milestones
The therapy has secured Fast Track, Breakthrough Therapy and Priority Medicines designations, with an FDA PDUFA target date set for April 2026. These designations aim to accelerate review and potential approval.
3. Manufacturing Challenges
Production of tividenofusp alfa demands precise protein engineering and robust biomanufacturing processes. Scaling to meet patient needs requires consistency in quality, stability and delivery across batches.